PharmaSphere, LLC is a biotechnology company that utilizes the TerraSphere technology to produce high-value, plant-based biocompounds for pharmaceutical and nutraceutical markets. Using the TerraSphere System allows PharmaSphere to achieve full environmental containment and controlled growth conditions, which result in increased production and reduced per-unit costs compared to traditional production methods.
PharmaSphere has achieved great success cultivating Madagascar Rosy Periwinkle, the source of the generic cancer chemotherapy compounds vincristine and vinblastine; artemisia, the source of the generic anti-malarial compound artemisinin; and transgenic tobacco, the source of insulin therapy for the treatment of diabetes.
ECAP has been instrumental in the formation and advancement of PharmaSphere. ECAP raised equity capital for technology development and market research, structured deal financing, and assembled the management team.